- Patient apheresis heterogeneity from prior systemic therapy, collection settings, anticoagulants, timing, and transport/cryopreservation cannot be “standardized away” and materially impacts identity, potency, and yields.
- Inadequate inclusion of clinically representative starting material during development drives nonrobust parameters, higher GMP batch failure rates, and reactive redesign that delays programs and jeopardizes last-line treatment delivery.
- Read the full article here: PharmTech
Bigger in Texas: Spilling the secrets on Houston’s biomanufacturing boom
An industry expert told us how recent projects in Houston speak to the city’s drive to become a premier biomanufacturing hub. Read the full article...